| Literature DB >> 15737555 |
Stefan Sleijfer1, Ate van der Gaast, André S Th Planting, Gerrit Stoter, Jaap Verweij.
Abstract
Statins are known to reduce mortality related to cardiovascular diseases. In recent years, evidence has accumulated that statins also exert anti-tumour activity for which numerous potential underlying mechanisms of action have been suggested. Accordingly, several case-control studies showed a reduction in cancer incidence in patients treated with statins. Furthermore, statins interact synergistically with several anti-tumour treatments in preclinical studies. Until now, only a few clinical studies are available that explore the optimal dose, feasibility, and efficacy of statins applied as single agents to control the growth of existing tumours. Studies investigating statins as part of a multi-drug regimen are completely lacking. Nevertheless, the interesting pre-clinical anti-tumour activity of statins combined with a favourable toxicity profile warrant their further development as anti-tumour agents, in particular as part of multi-drug regimens.Entities:
Mesh:
Substances:
Year: 2005 PMID: 15737555 DOI: 10.1016/j.ejca.2004.12.009
Source DB: PubMed Journal: Eur J Cancer ISSN: 0959-8049 Impact factor: 9.162